The results showed that both CDCA5 shRNA interference plasmid sequences could effectively reduce the expression level of CDCA5 in MDA-MB-231 cancer cells, and compared with that in MDA-ME-231 cells in the control group, the inhibition rate of 1MDA-ME-231 in the interference group was 39.01%, and the inhibition rate of 2MDA-ME-231 in the interference group was 42.98% (P < 0.05) (Figure 2). This evidence concerns the gene CDCA5 and cancer.